NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference
Rhea-AI Summary
NovaBridge (Nasdaq: NBP) announced management will present at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026. The company will appear in a fireside chat at 8:00 AM ET, and a webcast will be available on the company website for 90 days.
According to the company, the webcast link will be accessible via the News & Events page and the presentation runs within the conference held March 8-11, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – NBP
In the Mar 2 session, NBP gained 5.18%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.6% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Leadership change | Positive | +0.9% | Appointment of Emmett T. Cunningham Jr. as Vice Chairman and R&D committee member. |
| Feb 17 | Clinical trial update | Positive | +2.2% | First patient dosed in global randomized Phase 2 givastomig gastric cancer study. |
| Jan 20 | Insider share purchases | Positive | +5.1% | Executive Chairman’s plan to buy up to $5,000,000 of ADSs in the open market. |
| Jan 06 | Clinical data update | Positive | -11.2% | Positive Phase 1b givastomig dose expansion data in 1L metastatic gastric cancer. |
| Dec 30 | Index inclusion & bell | Positive | -1.7% | Announcement of Nasdaq Opening Bell ceremony and inclusion in Nasdaq Biotech Index. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally been positive (clinical progress, index inclusion, insider buying), with three positive price reactions and two instances where upbeat news coincided with negative moves.
Over the past few months, NovaBridge has highlighted its evolution into a global biotech platform with multiple clinical-stage assets, led by givastomig in first-line metastatic gastric cancer, which showed strong Phase 1b efficacy metrics and supported initiation of a global Phase 2 study in Q1 2026. The company also secured inclusion in the Nasdaq Biotech Index and announced substantial planned insider open‑market ADS purchases, including up to $5,000,000 by the Executive Chairman. Board strengthening via a new Vice Chairman and repeated investor presentations underscore a focus on visibility and capital markets engagement, which this Leerink conference appearance continues.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., March 02, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that NovaBridge’s management team will participate in the upcoming Leerink Partners 2026 Global Healthcare Conference being held on March 8-11, 2026.
Conference details are as follows:
Leerink Partners Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, March 11, 2026
Time: 8:00 AM ET
Webcast Link: Here
The webcast of the company presentation will be accessible on the News & Events page of the NovaBridge website for 90 days.
About NovaBridge
NovaBridge is a global biotechnology platform company committed to accelerating access to innovative medicines. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. By bridging science, strategy, and execution, NovaBridge enables transformative therapies to progress rapidly from discovery toward patients in need.
The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, Claudin 18.2 x 4-1BB bispecific antibody, and VIS-101, a potential best-in-class bifunctional biologic, targeting VEGF-A and ANG2.
Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. The product candidate is being evaluated in a global, randomized Phase 2 study, following the recent announcement of positive topline results from a Phase 1b, multi-center, open label study in first line gastric cancer. The Company is also collaborating with its partner, ABL Bio, for the development of ragistomig, a bispecific antibody integrating PD-L1 as a tumor engager and 4-1BB as a conditional T cell activator, in solid tumors. Additionally, NovaBridge owns worldwide rights outside of China to uliledlimab, an anti-CD73 antibody that targets adenosine-driven immunosuppression in cancer.
VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration and diabetic macular edema. VIS-101 is currently completing a randomized, dose-ranging Phase 2a study for wet AMD. NovaBridge is the majority shareholder of Visara, Inc., and Visara controls global rights to VIS-101, outside of Greater China and certain countries in Asia.
For more information, please visit www.novabridge.com and follow us on LinkedIn.
NovaBridge Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1-617-430-7579
pkelleher@lifesciadvisors.com
NovaBridge Biosciences
+1-240-745-6330
IR@novabridge.com
